Drug intelligence / Profile preview

iDD-005

Development stage: Preclinical
Lead developer: iDD Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

iDD-005 is a preclinical humanized monoclonal antibody developed by iDD biotech. It targets extracellular Cytokeratin 8 (eCK8) and is being developed for the treatment of various cancers, including colon, head and neck, glioma, and lung cancer. Promising preclinical data have shown tumor shrinkage in animal models, and the drug is being advanced towards a Phase I clinical trial.

Targets

KRT8 (Keratin, type II cytoskeletal 8)

Beyond the preview

Go deeper on iDD-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iDD-005.

Explore the full profile